openPR Logo
Press release

Aldosteronism Treatment Market Drivers and Restraints | 2018 - 2028 Key Players are Pfizer Inc., Allergan plc., GE Healthcare

03-05-2019 03:06 PM CET | Health & Medicine

Press release from: future market insights.

Aldosteronism Treatment Market Drivers and Restraints | 2018 -

Aldosteronism is a type of hormonal disorder that occurs due to an imbalance in aldosterone and further leads to high blood pressure. In Aldosteronism, aldosterone is produced in excess by the adrenal gland that exceeds the normal body requirement. This causes the sodium levels to increase and lowers the potassium levels in the body. High levels of sodium in the blood lead to a high volume of blood and ultimately high blood pressure. The Aldosteronism is of various types, primary aldosteronism (Conn’s syndrome) and secondary aldosteronism. Primary aldosteronism is due to a defect of the adrenal glands themselves, which leads to release too much aldosterone. Whereas in secondary aldosteronism aldosterone is released due to abnormal bodily functions or defect in genes and other medical disorders. Most cases of primary aldosteronism are caused by a noncancerous tumor of the adrenal gland. This condition is most common in people 30 to 50 years old. Hyperaldosteronism is also sever and common type of aldosteronism, it can caused because of hyperactivity in unilateral or both bilateral disease. Hyperaldosteronism leads to hypertension and lowers the potassium levels in body. In case of hypoaldosteronism there are lower aldosterone levels in body which further leads to complications. If the aldosteronism is not treated it can gradually increase the risk of heart attack and stroke, this provides the essential background for the aldosteronism treatment market growth. Various types of aldosteronism treatment are available amongst which the non-surgical aldosteronism treatment is mostly adopted by patients, in case of severe aldosteronism surgery are preferred by most medical professionals.

Aldosteronism Treatment Market: Drivers and Restraints

The increasing prevalence of primary aldosteronism due to sedentary lifestyle is the primary factor propelling the expansion of global aldosteronism treatment market. Besides this, the growing old population is the major driver for the aldosteronism treatment market growth. The rising prevalence of hypertension (high blood pressure) due to hectic and stressful lifestyle is also expected to create a high demand for aldosteronism treatment market. The growing efforts of research institutes & increasing number of research and development for developing new therapeutic drugs by many leading players in aldosteronism treatment market is expected to fuel the expansion of aldosteronism treatment market. As per the study published in 2016 by International Journal of Endocrinology & Metabolism the aldosteronism was projected to increase by 5% in recent years. The low cost of therapeutic drugs and aldosteronism diagnostic test is also expected to increase the demand for aldosteronism treatment market. However, the risk associated with surgical aldosteronism treatment such as excessive bleeding and side effects of the surgical procedure is expected to restrain the growth of aldosteronism treatment market during the forecast period.

A Sample Of This Report Is Available Upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8921

Aldosteronism Treatment Market: Segmentation

Tentatively, the global Aldosteronism Treatment Market has been segmented on the basis of treatment type, end user, and geography. Based on treatment type, global Aldosteronism Treatment Market is divided into following: Surgical aldosteronism treatment, Endocrine surgery, Adrenalectomy, Non-Surgical aldosteronism treatment, Palliative care, Drugs, Mineralocorticoid receptor antagonists, Calcium-channel blockers, Potassium sparring diuretics; Based on end users, global Aldosteronism Treatment Market is divided into following: Hospitals, Ambulatory Surgical Centers, Others.

Aldosteronism Treatment Market: Overview

The global aldosteronism treatment market is expected to witness significant growth over the forecast period owing to the increasing adoption of the treatment by the end users. The technological advancement further aided in increasing adoption rate of therapeutic drugs, as diagnosis of the aldosteronism due to CT scans, PET imaging technique provided the medical professional in brief about the disease situation. On the basis of treatment type, the non-surgical aldosteronism treatment segment is projected to register maximum market share in the terms of revenue over the forecast period owing to the better patient outcomes and availability of specific drugs according to the disease indications in the aldosteronism treatment market. The ambulatory surgical centers' segment in end users is expected to grow with the fastest CAGR in the aldosteronism treatment market owing to the increasing number of outpatient centers.

Aldosteronism Treatment Market: Regional Wise Outlook

Geographically, global aldosteronism treatment market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan (APEJ), Japan and the Middle East & Africa (MEA). North America is expected to be the leader in global aldosteronism treatment market owing to the high prevalence of hypertension in the region and higher expenditure of healthcare. Europe aldosteronism treatment market is projected to account for the second largest share in the aldosteronism treatment market over the forecast period due to higher spending on healthcare and greater adoption by the end users in the region. Asia-Pacific excluding Japan market for aldosteronism treatment is expected to grow with fast CAGR over the forecast period owing to the rising presence of manufacturers and increasing adoption by the patients.

Aldosteronism Treatment Market: Key Players

Some of the major players identified in the global aldosteronism treatment market are Pfizer Inc., Allergan plc., GE Healthcare, Novartis AG, Teva Pharmaceutical Industries Ltd., Accord Healthcare and Sun Pharmaceutical Industries Ltd, amongst others.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/toc/rep-gb-8921

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.
FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customised and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Future Market Insights
U.S. Office
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: abhishek.b@futuremarketinsights.com
FMI Blog:  https://www.fmiblog.com/
Web: https://www.futuremarketinsights.com
Blog: http://www.marketresearchblog.org/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Aldosteronism Treatment Market Drivers and Restraints | 2018 - 2028 Key Players are Pfizer Inc., Allergan plc., GE Healthcare here

News-ID: 1633779 • Views: 369

More Releases from future market insights.

Facial Implants Market 2018 - 2028 | Key Players Include Implatech Associates In …
Facial implants are a type of medical device used to correct the facial structure or to provide more defined facial features including cheeks or chin & jawline. Facial Implants products are used for cosmetic reasons & are also used in medical crises such as accidents and injuries. Facial implants are also designed for augmentative or reconstructive surgeries. Facial implants give long lasting and permanent results that are a key factor
Pericarditis Treatment Market 2018 - 2028 | Pfizer Inc., Bayer AG, PerkinElmer I …
Global Pericarditis Treatment: Market Insights  Pericarditis is a cardiovascular disease which represents the swelling of the pericardium wall of the heart. The main cause of pericardium disease is the inflammation of pericardium wall which is generally caused by viral infection. Other causes of pericarditis disease are renal failure, bacterial infections and intake of some drugs such as procainamide. Some of the common symptoms of pericarditis disease are shortness of breath, fatigue, rapid
Contouring Implants Market 2018 - 2028 | Key Players are ALPHA-HEALTH (ASIA) PTE …
Body Contouring refers to the medical-surgical procedure that alternates the shape of parts of the body via the removal of fat or skin. Body contouring implants procedures includes reshaping and resizing certain areas so the persons overall appearance is more balanced and in proportion. Body contouring implants are foreign materials that is made and molded prior to the person’s surgery and then inserted into the appropriate site. The body contouring
Multiple Endocrine Neoplasia Market 2018 - 2028 | Key Players Include West Coast …
Multiple Endocrine Neoplasia: Market Insights Multiple Endocrine Neoplasia is a disease caused by genetic mutation. Multiple Endocrine Neoplasia is inherited from one generation to another generation. The symptoms of the multiple endocrine neoplasia depends on the type of gland which is affected by the disease. The multiple endocrine neoplasia has been classified according to the gland which is affected by the disease. There are type 1 multiple endocrine neoplasia, Type 2A

All 5 Releases


More Releases for Aldosteronism

Aldosteronism Treatments Market Global Research and Clinical Survey Report 2020 …
The report discusses many vital industry facets that influence "Global Aldosteronism Treatments Market" industry acutely which includes extensive study of competitive edge, latest advancements, region-wise industry environment, contemporary market and manufacturing trends, leading market contenders, and current consumption tendency of the end user. The report also oversees market size, market share, growth rate, revenue, and CAGR reported previously along with its forecast estimation. (Special Offer: Available up-to 30% Discount for a
Primary Aldosteronism Market Grow At A CAGR Of 8.40% by 2023 | Topmost Players P …
Market Research Future published a research report on Global Primary Aldosteronism Market and Provide Overview of Key Players and their Strategic Profiling in the Market, Comprehensively Analyzing their Core Competencies, and Drawing a Competitive Landscape for the Market. Primary Aldosteronism Market - Market Highlights Increasing prevalence of primary aldosteronism, growing geriatric population, rising number of obese individuals in the developing as well as the developed regions and increasing consumption of alcohol are
Primary Aldosteronism Market by Biopsy & Endoscopy Based, Imaging Procedure and …
The Global Primary Aldosteronism Market is segmented on the basis of type, indications, diagnosis, treatment and end users. On the basis of type, the market is segmented as Type I, and Type II. On the basis of indications, the market is categorized into heart attack, kidney failure, stroke, and others. On the basis of diagnosis, the market is segmented into blood test, imaging, and others. The blood test segment is sub-segmented
Primary Aldosteronism Market 2018 Key Country Analysis: Pfizer Inc., Sun Pharmac …
This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the Global Primary Aldosteronism Market over the forecast period. Market Scenario: The adrenal glands within the body produce some essential hormones like aldosterone. This hormone balances the levels of sodium and potassium in the blood. Primary aldosteronism is a medical condition in which the adrenal glands produce high
Primary Aldosteronism Market Highlight, by type and Treatment Topmost Leading Ke …
Primary Aldosteronism Market research report, Type (type I, type II), Indication (heart attack, kidney failure, stroke), by Diagnosis (blood test, imaging), Treatment (surgery, aldosterone antagonists), End User (hospitals) - Global forecast till 2023. The global primary aldosteronism market is expected to grow at a CAGR of 8.40% during forecast period. KEY PLAYERS FOR PRIMARY ALDOSTERONISM MARKET The key players for the global primary aldosteronism market are Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd.